Solventum Corp <SOLV.N>: UBS assumes coverage with Buy vs Neutral rating; target price $95 vs $78
SOLV•Related News
ABM partners with LaGuardia Gateway Partners to pilot autonomous robots at LaGuardia Terminal B
ABM•
Tenax Therapeutics Inc <TENX.O>: Canaccord Genuity initiates coverage with buy rating; target price $35
TENX•
Orange reports first-half 2026 financial report is available
ORAN•
Baxter <BAX.N>: UBS assumes coverage with neutral rating; target price $25 vs $19
BAX•
Cinemark Holdings Inc <CNK.N>: Baird Raises Target Price To $40 From $37
CNK•